These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 22841345)

  • 1. Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia.
    Matza LS; Phillips GA; Revicki DA; Ascher-Svanum H; Malley KG; Palsgrove AC; Faries DE; Stauffer V; Kinon BJ; George Awad A; Keefe RS; Naber D
    Psychiatry Res; 2012 Dec; 200(2-3):835-42. PubMed ID: 22841345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a clinician questionnaire and patient interview to assess reasons for antipsychotic discontinuation.
    Matza LS; Phillips GA; Revicki DA; Ascher-Svanum H; Kaiser D; Stauffer V; Shorr JM; Kinon BJ
    Psychiatry Res; 2011 Oct; 189(3):463-8. PubMed ID: 21684017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives.
    Ascher-Svanum H; Nyhuis AW; Stauffer V; Kinon BJ; Faries DE; Phillips GA; Schuh K; Awad AG; Keefe R; Naber D
    Curr Med Res Opin; 2010 Oct; 26(10):2403-10. PubMed ID: 20812791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial.
    Faries D; Ascher-Svanum H; Phillips G; Nyhuis AW; Sugihara T; Stauffer V; Kinon BJ
    BMC Med Res Methodol; 2012 Sep; 12():142. PubMed ID: 22974273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation.
    Matza LS; Phillips GA; Revicki DA; Ascher-Svanum H; Malley KG; Palsgrove AC; Faries DE; Stauffer V; Kinon BJ; Awad AG; Keefe RS; Naber D
    Patient Prefer Adherence; 2012; 6():521-32. PubMed ID: 22879738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder.
    Tandon R; Devellis RF; Han J; Li H; Frangou S; Dursun S; Beuzen JN; Carson W; Corey-Lisle PK; Falissard B; Jody DN; Kujawa MJ; L'italien G; Marcus RN; McQuade RD; Ray S; Van Peborgh P;
    Psychiatry Res; 2005 Sep; 136(2-3):211-21. PubMed ID: 16115690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients.
    Vernon MK; Revicki DA; Awad AG; Dirani R; Panish J; Canuso CM; Grinspan A; Mannix S; Kalali AH
    Schizophr Res; 2010 May; 118(1-3):271-8. PubMed ID: 20172695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
    Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors related to different reasons for antipsychotic drug discontinuation in the treatment of schizophrenia: a naturalistic 18-month follow-up study.
    Vita A; Barlati S; Deste G; Corsini P; De Peri L; Sacchetti E
    Psychiatry Res; 2012 Dec; 200(2-3):96-101. PubMed ID: 22858250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Ratner Y; Gibel A; Yorkov V; Ritsner MS
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relationships between insight and medication adherence in subjects with psychosis].
    Droulout T; Liraud F; Verdoux H
    Encephale; 2003; 29(5):430-7. PubMed ID: 14615692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia.
    Wehmeier PM; Kluge M; Schacht A; Helsberg K; Schreiber W; Schimmelmann BG; Lambert M
    J Psychiatr Res; 2008 Jul; 42(8):676-83. PubMed ID: 17720192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A global measure to assess switching antipsychotic medications in the treatment of schizophrenia.
    Targum SD; Pestreich L; Reksoprodjo P; Pereira H; Guindon C; Hochfeld M
    Hum Psychopharmacol; 2012 Sep; 27(5):455-63. PubMed ID: 22826027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
    Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients.
    Karagianis J; Novick D; Pecenak J; Haro JM; Dossenbach M; Treuer T; Montgomery W; Walton R; Lowry AJ
    Int J Clin Pract; 2009 Nov; 63(11):1578-88. PubMed ID: 19780867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The psychopathological characteristics of treatment discontinuation group in 6-month treatment with paliperidone ER.
    Thavichachart N; Kongsakon R; Lo WT; Lim L; Singh S; Sobrevega E; Banaag C; Bautista J; Evangelista ML; Dimatalac B; Choi A; Nerapusee O
    Int J Clin Pract; 2012 Oct; 66(10):969-75. PubMed ID: 22994331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial.
    Weiden PJ
    J Clin Psychiatry; 2007; 68 Suppl 1():12-9. PubMed ID: 17286523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of type of treatment on the well-being of Spanish patients with schizophrenia and their caregivers.
    Fe Bravo-Ortiz M; Gutiérrez-Casares JR; Rodríguez-Morales A; García MA; Hidalgo-Borrajo R
    Int J Psychiatry Clin Pract; 2011 Nov; 15(4):286-95. PubMed ID: 22122003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
    Parellada E; Andrezina R; Milanova V; Glue P; Masiak M; Turner MS; Medori R; Gaebel W
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):5-14. PubMed ID: 16144781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.